Blueprint gets first FDA approval, with second expected this year

FDA approved Blueprint’s gastrointestinal stromal tumor therapy a month ahead of its Feb. 14 PDUFA date, notching the biotech the first

Read the full 214 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE